Is there a role for retinoids to treat minimal residual disease in neuroblastoma?

Por Matthay, K K, Reynolds, C P
Publicado em 2000

The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma

Por Tagde, A, Singh, H, Kang, M H, Reynolds, C P
Publicado no Blood Cancer J (2014)

Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.

Por Yee, D, Favoni, R E, Lebovic, G S, Lombana, F, Powell, D R, Reynolds, C P, Rosen, N
Publicado em 1990

Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system.

Por Thiele, C J, McKeon, C, Triche, T J, Ross, R A, Reynolds, C P, Israel, M A
Publicado em 1987

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models

Por Cai, W, Maldonado, N V, Cui, W, Harutyunyan, N, Ji, L, Sposto, R, Reynolds, C P, Keshelava, N
Publicado em 2010

Olfactory neuroblastoma is a peripheral primitive neuroectodermal tumor related to Ewing sarcoma.

Por Sorensen, P H, Wu, J K, Berean, K W, Lim, J F, Donn, W, Frierson, H F, Reynolds, C P, López-Terrada, D, Triche, T J
Publicado em 1996

High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification.

Por Hailat, N, Keim, D R, Melhem, R F, Zhu, X X, Eckerskorn, C, Brodeur, G M, Reynolds, C P, Seeger, R C, Lottspeich, F, Strahler, J R
Publicado em 1991